| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL4a2 |
| Uniprot No | P08572 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1493-1712aa |
| 氨基酸序列 | VKHSQTDQEPMCPVGMNKLWSGYSLLYFEGQEKAHNQDLGLAGSCLARFS TMPFLYCNPGDVCYYASRNDKSYWLSTTAPLPMMPVAEDEIKPYISRCSV CEAPAIAIAVHSQDVSIPHCPAGWRSLWIGYSFLMHTAAGDEGGGQSLVS PGSCLEDFRATPFIECNGGRGTCHYYANKYSFWLTTIPEQSFQGSPSADT LKAGLIRTHISRCQVCMKNL |
| 预测分子量 | 168 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于COL4A2重组蛋白的参考文献示例(注：文献信息为模拟概括，非真实存在)：
---
1. **文献名称**: "Recombinant COL4A2 expression in mammalian cells reveals impaired secretion in pathogenic mutations"
**作者**: Smith J, et al.
**摘要**: 研究通过哺乳动物细胞表达重组COL4A2蛋白，发现与遗传性脑血管病相关的点突变(如Gln1432Glu)会导致蛋白分泌障碍，并破坏COL4A1/A2异源三聚体的形成，提示突变通过影响胶原IV的分泌导致基底膜结构异常。
---
2. **文献名称**: "Structural and functional analysis of the COL4A2 C-terminal domain using recombinant fragments"
**作者**: Tanaka K, et al.
**摘要**: 利用大肠杆菌系统表达COL4A2羧基端重组蛋白片段，通过X射线晶体学解析其结构，揭示该区域在胶原IV网络自组装中的关键作用，并证明其与整合素结合的分子机制。
---
3. **文献名称**: "COL4A2 recombinant protein inhibits angiogenesis in a zebrafish model"
**作者**: Lee H, et al.
**摘要**: 通过昆虫细胞表达系统制备全长重组COL4A2蛋白，发现其在斑马鱼模型中抑制血管新生，机制可能与竞争性阻断内皮细胞表面受体(如CD36)介导的信号通路相关，为抗血管生成治疗提供新靶点。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词："recombinant COL4A2 protein"或"COL4A2 expression"。
COL4A2 (Collagen Type IV Alpha 2 Chain) is a critical component of type IV collagen, a major structural protein in basement membranes. It forms heterotrimers with COL4A1. creating a network essential for tissue integrity and cell-matrix interactions. Mutations in COL4A2 are linked to cerebrovascular, renal, and ocular disorders, including porencephaly, hemorrhagic stroke, and Alport syndrome. Recombinant COL4A2 protein is engineered to study its biological roles, disease mechanisms, and therapeutic potential.
Produced via mammalian expression systems (e.g., HEK293 or CHO cells), recombinant COL4A2 retains post-translational modifications crucial for stability and function. It typically includes key domains like the 7S region and NC1 domain, enabling structural studies or interaction assays. Researchers use it to model basement membrane assembly, vascular development, and pathogenic mutations.
Applications span in vitro studies (e.g., cell adhesion, angiogenesis assays) and disease modeling. It also aids in developing antibodies or gene therapies targeting COL4A2-related pathologies. Recent advances in structural biology and gene-editing tools (e.g., CRISPR) have intensified demand for high-purity recombinant COL4A2 to explore its role in tissue-specific basement membrane variations and mutation-driven pathologies.
×
